Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Drugmakers Go on Trial Over Opioid Epidemic

04/18/2021 | 09:14am EDT

By Sara Randazzo

Four drugmakers are slated to go on trial Monday in California over claims they fed the opioid crisis, in a proceeding that could help finalize multibillion-dollar settlements between state and local governments and pharmaceutical companies.

The case is just the second to go to trial out of thousands of similar lawsuits accusing the drug industry of fueling an opioid epidemic that has killed nearly 500,000 people since 1999, according to federal data.

In the trial set to begin Monday fully by videoconference, four California communities allege that Johnson & Johnson, Teva Pharmaceutical Ltd., Allergan and Endo International PLC ran misleading marketing campaigns that played down the risks of opioid addiction to boost sales of powerful prescription painkillers.

"So many families have been affected, so many lives have ended or been completely devastated," said Santa Clara County Counsel James Williams, whose county will be pursuing its claims at trial alongside those of Los Angeles and Orange counties and the city of Oakland. "Now the question is, how is there a measure of accountability for these manufacturers?"

The concept of legally pinning blame for the opioid crisis on the pharmaceutical industry was a novelty when the case going to trial was filed in May 2014. Since then, nearly every state and more than 3,000 counties, Native American tribes, hospitals and others have sued companies up and down the drug supply chain.

The companies are expected to argue at trial that they marketed their drugs responsibly with regulatory oversight and that each had a small fraction of the pill market in the California communities. A Teva spokeswoman said the company will vigorously defend itself against the claims but is also ready to settle the opioid litigation nationally. J&J said it will challenge the claims and that it worked with regulators to provide appropriate information on the risks and benefits of its prescription opioids. AbbVie Inc., which acquired Allergan in 2020, and Endo declined to comment.

Only one other opioid case has gone to trial, resulting in a $465 million judgment against Johnson & Johnson in Oklahoma in 2019. The company is appealing. Several trials slated to take place last year were delayed because of the coronavirus pandemic but are once again approaching.

The California trial, along with trials expected to start in West Virginia federal court in May and New York state court in June, could spur drugmakers and distributors to finalize settlements to end the lawsuits nationwide.

J&J, along with the three largest drug distributors in the country, McKesson Corp., AmerisourceBergen Corp. and Cardinal Health Inc., have offered to pay a collective $26 billion to resolve their piece of the litigation. Talks between the companies and states have been under way since late 2019 but have been delayed by the pandemic as well as details around attorneys' fees and how to account for communities that opt out of the deal.

Israel-based Teva also made a proposal in 2019 to resolve the cases, offering to donate a decade's worth of opioid-addiction treatment drugs along with a cash payment of $250 million.

OxyContin maker Purdue Pharma LP, one of the original targets of the California case and the broader opioid litigation, filed for bankruptcy in 2019 to resolve the liabilities and is currently negotiating a $10 billion payment plan with creditors.

The first phase of the trial, expected to last for months, would determine if the companies are liable. If Orange County Superior Court Judge Peter Wilson decides that they are, the counties next would argue that they deserve billions of dollars in penalties and money to help abate the impacts of opioid addiction.

Write to Sara Randazzo at sara.randazzo@wsj.com

(END) Dow Jones Newswires

04-18-21 1114ET

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.65% 114.74 Delayed Quote.7.08%
AMERISOURCEBERGEN CORPORATION -0.28% 115.48 Delayed Quote.18.13%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) 0.14% 0.75913 Delayed Quote.-1.58%
BRITISH POUND / US DOLLAR (GBP/USD) 0.07% 1.3921 Delayed Quote.2.14%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) 0.09% 0.81214 Delayed Quote.3.49%
CARDINAL HEALTH, INC. -0.16% 56.19 Delayed Quote.4.91%
DJ INDUSTRIAL 0.95% 34196.82 Delayed Quote.10.68%
ENDO INTERNATIONAL PLC 3.38% 4.89 Delayed Quote.-31.89%
EURO / US DOLLAR (EUR/USD) 0.09% 1.19368 Delayed Quote.-2.33%
INDIAN RUPEE / US DOLLAR (INR/USD) -0.05% 0.01348 Delayed Quote.-1.49%
JOHNSON & JOHNSON 0.46% 163.37 Delayed Quote.3.81%
MCKESSON CORPORATION 0.08% 188.98 Delayed Quote.8.66%
MERIDIAN ENERGY LIMITED 0.58% 5.21 End-of-day quote.-29.78%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) 0.20% 0.70747 Delayed Quote.-1.87%
REECE LIMITED -1.44% 23.2 End-of-day quote.56.76%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2.16% 10.42 Delayed Quote.7.98%
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
06/24TEVA PHARMACEUTICAL INDUSTRIESá : Announces Ministry of Health Labour and Welfar..
AQ
06/23TEVA PHARMACEUTICAL INDUSTRIESá : Announces Its Launch of the First Generic PERF..
AQ
06/23TEVA PHARMACEUTICAL INDUSTRIESá : Secures Japanese Approval for Ajovy Injection ..
MT
06/23TEVA PHARMACEUTICAL INDUSTRIESá : Announces Ministry of Health, Labour and Welfa..
BU
06/22TEVA PHARMACEUTICAL INDUSTRIESá : Launches First Generic Version of Perforomist ..
MT
06/22TEVA PHARMACEUTICAL INDUSTRIESá : Announces Its Launch of the First Generic PERF..
BU
06/22TEVA PHARMACEUTICAL INDUSTRIES LTDá : . - New Data Supporting the Safety and Eff..
AQ
06/22TEVA PHARMACEUTICAL INDUSTRIESá : Says Study Suggests Safety of Copaxone for Bre..
MT
06/22NEW SAFETY DATA ON TREATMENT WITH CO : COBRA study presented at the 7th Congress..
BU
06/21TEVA PHARMACEUTICAL INDUSTRIESá : Presents New Data at 7th European Academy of N..
BU
More news
Financials (USD)
Sales 2021 16 621 M - -
Net income 2021 1 496 M - -
Net Debt 2021 22 064 M - -
P/E ratio 2021 8,51x
Yield 2021 -
Capitalization 11 428 M 11 428 M -
EV / Sales 2021 2,02x
EV / Sales 2022 1,84x
Nbr of Employees 37 736
Free-Float 90,3%
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 10,42 $
Average target price 12,33 $
Spread / Average Target 18,3%
EPS Revisions
Managers and Directors
NameTitle
Kňre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir Executive VP-Global Research & Development
Eric DrapÚ Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED7.98%11 187
JOHNSON & JOHNSON3.34%428 269
ROCHE HOLDING AG10.19%321 632
PFIZER, INC.6.09%218 590
NOVARTIS AG1.55%207 926
ABBVIE INC.6.39%201 349